Nuclear medicine has a huge potential in treating cancer and cardiac diseases. Growth of medical imaging is an opportunity for the growth of the global nuclear medicine radioisotope market, as both markets are correlated. Radiopharmaceuticals are approved by the Food and Drug Administration (FDA) as either drugs or biologics.

The global Nuclear Medicine Radioisotopes market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Nuclear Medicine Radioisotopes volume and value at global level, regional level and company level. From a global perspective, this report represents overall Nuclear Medicine Radioisotopes market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Agfa-Gevaert Group
Braco
Cardiarc
Cardinal Health
CMR Naviscan (Gamma Medica Inc.)
Curium
Digirad
GE Healthcare
Nordion (Canada)
NTP Radioisotopes SOC
Positron
Segami
Siemens Healthcare

Segment by Regions
North America
Europe
China
Japan

Segment by Type
Thallium-201 (Tl-201)
Iodine (I-123)
Fluorine-18
Rubidium-82 (Rb-82)
Other

Segment by Application
Tumor
Heart Disease
Lymphoma
Thyroid Gland
Other